EYPT

Business Context and Reporting Period

Company: pSivida Corp. (Note: Input metadata referenced "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2010
Business Overview: pSivida develops sustained-release drug delivery products for chronic eye diseases using two core technologies: Durasert (polymer-based) and BioSilicon (erodible silicon). The company has no internal sales force and relies on strategic collaborations for commercialization.

Key Financial Metrics

Liquidity: The company held approximately $17.6 million in cash, cash equivalents, and marketable securities as of June 30, 2010. Management believes this is sufficient to fund operations into at least calendar year 2012.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased 90% year-over-year, driven primarily by the full payment of a $15.0 million conditional note by partner Alimera Sciences in April 2010, following Alimera's IPO.
• Profitability: The company reported a net income of $8.8 million in 2010, a reversal from a $2.5 million net loss in 2009. This turnaround was largely due to the non-recurring revenue recognition from the Alimera note payment.
• Expense Reduction: Operating expenses decreased by 17% to $14.0 million, with R&D dropping 13% and General & Administrative costs dropping 21% due to the absence of prior-year legal fees related to reincorporation and provisions for losses on notes receivable.
• Derivative Liability: The company recorded a $339,000 expense for the change in fair value of derivative liabilities (A$-denominated warrants) in 2010, compared to $959,000 of income in 2009.

Guidance, Outlook, and Risks

Outlook and Catalysts:

• Iluvien Approval: The primary business catalyst is the FDA review of Iluvien (licensed to Alimera) for Diabetic Macular Edema (DME). The FDA granted Priority Review status in August 2010, with a decision expected by the end of calendar year 2010.
• Milestone Payments: Upon FDA approval of Iluvien, pSivida is entitled to a $25.0 million milestone payment from Alimera, plus a 20% profit share on future sales.
• Retisert Royalties: The company resumed receiving 100% of royalties on Retisert sales from Bausch & Lomb in August 2010 after a $6.25 million royalty advance agreement concluded.

Risks and Contingencies:

• Regulatory Risk: Future profitability is heavily dependent on the FDA approval of Iluvien. If approval is denied or delayed, the company may require additional capital.
• Collaboration Dependency: The company relies entirely on partners (Alimera, Pfizer, Bausch & Lomb) for product development and commercialization. Partners can terminate agreements with short notice.
• Intangible Asset Impairment: The company holds $23.9 million in intangible assets (Durasert and BioSilicon technologies). Future impairment charges could materially impact results if commercialization prospects diminish.
• Derivative Volatility: Fluctuations in the company's stock price will continue to impact earnings through the revaluation of A$-denominated warrants until they expire in July 2012.

Investor Verification Checklist

• FDA Decision Timeline: Verify the status of the FDA's Priority Review decision for Iluvien (expected end of 2010).
• Alimera Commercialization: Confirm Alimera's ability to launch Iluvien and the timeline for the $25 million milestone payment.
• Derivative Liability Exposure: Monitor the fair value of outstanding A$-denominated warrants and their impact on quarterly earnings.
• Capital Runway: Assess the company's cash burn rate relative to the $17.6 million cash position to determine if additional financing is needed before 2012.
• Retisert Royalty Trends: Review Bausch & Lomb sales data for Retisert to gauge the sustainability of royalty income post-advance agreement.